Recombinant MS4A1 (Obinutuzumab Biosimilar) antibody

Catalog No. ABIN7487892

The Mammalian Cells Monoclonal anti-MS4A1 (Obinutuzumab Biosimilar) antibody has been validated for ELISA. It is suitable to detect MS4A1 (Obinutuzumab Biosimilar) in samples from Human.

Quick Overview for Recombinant MS4A1 (Obinutuzumab Biosimilar) antibody (ABIN7487892)

Target: MS4A1 (Obinutuzumab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Mammalian Cells

Clonality: Monoclonal

Conjugate: This MS4A1 (Obinutuzumab Biosimilar) antibody is un-conjugated

Application: ELISA

Grade: Research Grade

Product Details anti-MS4A1 (Obinutuzumab Biosimilar) Antibody

Expression System: Mammalian cells

Purpose: Obinutuzumab Biosimilar - Anti-MS4A1, CD20 mAb

Characteristics: Antibody Type: IgG1-kappa

Purification: Recombinant antibody expressed in mammalien cells and purified.

Isotype: IgG1 kappa

Application Details

Restrictions: For Research Use only

Handling

Buffer: PBS pH 7.5

Storage: -80 °C

Storage Comment: store at -80°C

Target Details for MS4A1 (Obinutuzumab Biosimilar)

Target: MS4A1 (Obinutuzumab Biosimilar)

Target Type: Biosimilar

Background: GA101,RG7159,RO5072759,afutuzumab
Obinutuzumab is a humanized monoclonal antibody that can be used in combination with chlorambucil to treat chronic lymphocytic leukemia. It was sold under the Gazyva brand. There are black box warnings of fatal hepatitis B virus (HBV) reactivation and fatal progressive multifocal leukoencephalopathy (PML).

CAS-No: 949142-50-1